takeaway
miss core growth expect vs trim rev/
ep guidanc mostli cautiou view around eu industri market said
posit pharma rebound china instrument bull hang
hat look ahead setup new product cycl interest
stock alreadi seem discount growth recoveri view risk/reward
bounc back acceler nice stack comp driven loosen capit
spend budget larg us/eu custom direct better china gener
demand earli winner round tender unlik much past year
least one major pharma market usual sync given
star align improv stabil evid across geographi includ
china dd us/eu msd look ahead guidanc assum sustain pharma
trend msd
china improv q/q gener pharma headwind thaw china grew
reflect nice bounc back q/q improv mainli driven
biopharma dd gener custom re-start capital-expenditure buy initi
relat delay off-set on-going declin food test volum
shift privat lab expect surpris see instrument demand
gener market return posit y/i growth soon visibl remain low
round tender like later year year guidanc factor core
growth china
outlook cut industri eu caution lower core growth
outlook cut ep mid-pt
driven slower show increment weaker industri outlook
echo theme particularli eu despit normal pharma capital-expenditure budget
global revis outlook doesnt seem overli heroic core vs
hing biopharma demand hold steadi
stock buy-back anoth tap
may continu keep floor stock look easi comp
 stepped-up new product flow hold promis soon make strong case
normal year rel lt core growth target yet
stock ebitda line w/ peer despit below-p growth valuat
alreadi seem reflect confid growth recoveri next year view
remain sidelin pend greater confid around potenti
newer product intro convict abil drive sustain better organ growth
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
pleas see import disclosur inform page report
share repurchas
share repurchas
ep opm expans
price target impli ev ebitda
strong uptak new product launch
share repurchas
price multipl ev
stepped-up invest restor top-line growth
heighten competit pressur lc mass spec
price multipl ev
wat core focu three analyt technolog market
thermal analysi astut concentr
asset util disciplin capit redeploy
philosophi contribut
above-averag
profit industry-lead profil
cautiou wat exposur
rev end-market
deceler year sinc
lean heavili success
upcom new product cycl soon call/
quantifi abat china/eu headwind
pleas see import disclosur inform page report
water corporationwat result versu expectationsquarterli result versu expect million except per share million except per share vs growthv expectationsprior yearforecastreportedactualpercentactualpercentepsnet product expens share share analysisgross research sg oper incom incom net equiti research
pleas see import disclosur inform page report
water corporationhistor project valuat summarydollar million except per share amount fiscal year end decemb histor earn per flow cash cash flow cash flow per cash net interest free cash stock-bas sheet metricsreceiv day day day convers interest debt ttm debt ttm valu per water corpor jefferi llc estim equiti research
pleas see import disclosur inform page report
